Genetic Risk, Adherence to a Healthy Lifestyle, and Ischemic Heart Disease
| Autor: | Sibu P. Saha, Thomas F. Whayne |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Physical fitness
Hypercholesterolemia Single-nucleotide polymorphism Disease Coronary Artery Disease 030204 cardiovascular system & hematology Bioinformatics Coronary artery disease 03 medical and health sciences 0302 clinical medicine Risk Factors Diabetes mellitus Medicine Humans Genetic Predisposition to Disease 030212 general & internal medicine Healthy Lifestyle Allele Family history biology business.industry Lipoprotein(a) medicine.disease biology.protein Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business |
| Zdroj: | Current cardiology reports. 21(1) |
| ISSN: | 1534-3170 |
| Popis: | The purpose of this review is to investigate and discuss two aspects of coronary artery disease (CAD)—genetic risk and therapeutic lifestyle change (TLC)—both of which have key importance for patients and their care but which actually receive inadequate attention. Genetic risk has generally been relegated to a broad association with the presence of one or more inherited cardiovascular (CV) risk factors such as hypercholesterolemia, family history of atherosclerosis, hypertension, and diabetes mellitus. However, the future of genetic risk is an understanding of specific genes, a genetic risk score, specific genetic loci known as selective nucleotide polymorphisms (SNPs), specific alleles, and microribonucleic acids (miRNAs). Healthy lifestyle is fashionably referred to as TLC and encompasses physical fitness, exercise, behavioral modification, diet, and stress reduction. In the past decade, aggressive treatment of cholesterol with statins has received the major emphasis for CV risk reduction. Genetics, of course, can only be modified by factors that influence epigenetics, and TLC could have an effect on genetics by this mechanism. On the other hand, each individual component of TLC has been shown to contribute to a reduction of CV risk. Although aggressive pharmaceutical approaches are now in vogue, whatever TLC can contribute, depending on the degree of individual patient adherence, should never be forgotten. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink